Algorae Pharmaceuticals Ltd (asx:1AI) Share Price

Company Profile

Business description
Algorae Pharmaceuticals Ltd is a clinical-stage pharmaceutical company developing transformative solutions for under met medical needs in the community. The firm develops AlgoraeOS, a closed-loop platform, leveraging computational tools to generate novel insights in silico that are being developed to initiate or accelerate therapeutic programs. The products of the company comprise AI-116, a novel combination drug candidate of cannabidiol (CBD) and an off-patent pharmaceutical ingredient. The company is conceptualized to be a potential treatment for dementia, including Alzheimer’s disease, NTCELL is an alginate-coated capsule containing clusters of neonatal porcine choroid plexus cells. It also offers LP-003 Anti-obesity Drug and LC-002 migraine treatment.
Contact
525 Collins Street
Level 23, Rialto South Tower
MelbourneVIC3000
AUS
T: +61 422180317
https://www.algoraepharma.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
48

Recommended

Siteminder’s newly released product for hotel owners and travel agents could widen its moat and see revenue accelerate further.

Joseph Taylor | 16 September 2025

Working to prevent repeated failures could also improve competitiveness.

Nathan Zaia | 15 September 2025

Acquisition unlikely to improve prospects in the US and detracts from other opportunities.

Roy Van Keulen | 15 September 2025

Index	Last price	Change	% Change
All Ordinaries	9,151.20	1.30	-0.01%
CAC 40	7,818.22	78.71	-1.00%
DAX 40	23,329.24	419.62	-1.77%
Dow JONES (US)	45,757.90	125.55	-0.27%
FTSE 100	9,195.66	81.37	-0.88%
HKSE	26,438.51	8.05	-0.03%
NASDAQ	22,333.96	14.79	-0.07%
Nikkei 225	44,902.27	134.15	0.30%
NZX 50 Index	13,234.89	26.58	0.20%
S&P 500	6,606.76	8.52	-0.13%
S&P/ASX 200	8,877.70	3.00	-0.03%
SSE Composite Index	3,861.86	1.36	0.04%